

## Hikma Ventures invests in Propeller Health for the enhancement of leading respiratory technology platform

**London, 20 October 2016** – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its venture capital arm, Hikma International Ventures and Development LLC (Hikma Ventures) has participated in a \$21.5 million series C round of financing for Propeller Health.

Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from chronic obstructive pulmonary disease (COPD), asthma and other respiratory diseases. This technology provides a novel combination of sensors, mobile applications, data analytics and personalised feedback, encouraging patient adherence to maintenance therapy. The Propeller Health device and technology has been used by patients with respiratory diseases in over 40 commercial programmes across the U.S., including major healthcare systems, payers and employers. The Propeller Health device is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers, and other inhaler devices (dry powder inhaler and soft mist inhaler). Propeller has partnered with several companies including Vectura Group to develop an add-on sensor for Vectura's lever-operated multi-dose inhaler.

Hikma Ventures' investment will be supporting the expansion of Propeller Health's digitally guided therapy platform and modernise the management of respiratory disease. The market size for digital dose inhalers for asthma and COPD is expected to reach around \$3.6 billion in 2024<sup>1</sup>

Lana Ghanem, Managing Director of Hikma Ventures, said, *"Our investment in Propeller Health demonstrates our focus on identifying and investing in innovative, high potential digital health providers. We are very excited to be supporting the development of Propeller's technology platform, which is enabling physicians, patients and providers to have advanced access to better quality data as well as improved medication adherence in the growing respiratory segment."*

David Van Sickle, CEO of Propeller Health, said, *"Despite an abundance of effective treatments, the majority of people with chronic respiratory disease could be doing much better than they are. We're excited to work with Hikma Ventures on our efforts to develop information-powered medicines that help people and their physicians achieve control of these conditions."*

-- ENDS --

### Enquiries

#### Hikma Pharmaceuticals PLC

Lana Ghanem, Managing Director, Hikma Ventures

Susan Ringdal, VP Corporate Strategy and Investor Relations

+962(0)6 5802900/ +962 79 8579391

+44 (0)20 7399 2760/ +44 7776 477050

#### FTI Consulting

Ben Atwell/ Matthew Cole

+44 (0)20 3727 1000

### **About Hikma**

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (MENA) and Europe. For more information, visit [www.hikma.com](http://www.hikma.com)

### **About Hikma Ventures**

Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, visit [www.hikmaventures.com](http://www.hikmaventures.com)

### **About Propeller Health**

Propeller empowers people with asthma and COPD to live measurably better lives. In 2010 Propeller set out to modernize respiratory medicine, empower people to minimize the impact of asthma and COPD on their daily lives, and connect them to their physicians, environment and community. Propeller’s information-powered approach to respiratory management guides physicians and patients to the optimal path of therapy for each individual. With connected inhalers, digital interfaces, and real time personalized insights, participants receive personal guidance and expert direction anytime. Backed by 3M Ventures (NYSE: MMM), SR One, Hikma Ventures (LON: HIK),, Safeguard Scientifics (NYSE: SFE), Social Capital and other investors, Propeller has been used by patients with asthma or COPD in over 45 commercial programs across the US at major healthcare systems, payers, employers and other commercial partners. The company has been recognized as the recipient of the American Telemedicine Association’s 2016 President’s Award for Innovation in Remote Healthcare and as one of the top “Fierce 15” medical device companies in 2015 by FierceMedicalDevices. For more information, visit [www.propellerhealth.com](http://www.propellerhealth.com)

---

<sup>1</sup> Digital Dose Inhaler Market Analysis By Product, Grand View Research, July 2014